Abousheishaa Aya Ahmed, Lazim Nor Hazila Mat, Tang Song Ling, Sulaiman Ahmad Hatim, Huri Hasniza Zaman, Guan Ng Chong
Department of Psychological Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.
Faculty of Languages and Linguistics, University of Malaya, Kuala Lumpur, Malaysia.
Patient Educ Couns. 2022 Jul;105(7):2466-2474. doi: 10.1016/j.pec.2021.11.007. Epub 2021 Nov 20.
This study aimed to develop and assess the effectiveness of an encounter decision aid for Malaysian patients with MDD to support treatment decision-making during the consultation.
The decision aid prototype was developed following a literature review and six focus groups. Alpha testing assessed its comprehensibility, acceptability, usability and desirability through user-centered cognitive interviews. Beta-testing evaluated preliminary evidence on its efficacy using the SDM Scale and PDMS. Feasibility was assessed by timing the consultation.
The alpha testing demonstrated that the decision aid was patient-oriented, comprehensible, comprehensive, concise and objective with an appealing design. Beta-testing indicated that PtDA significantly increased patients satisfaction with SDM from patients' [83.32 (13.92) vs 85.76 (13.80); p < 0.05] and physicians' [81.07 (10.09) vs 86.36 (10.10); p < 0.05] perspectives and prepared the patients for decision making from the patients' [PDMS patients: 84.10 (12.69)] and physicians' [PDMS physicians: 83.78 (16.62)] perspectives as well. There was no change in the consultation time between the control and the intervention groups.
We developed an antidepressant PtDA for Malaysian patients with MDD that increases patients' involvement in shared decision making and enhances their preparedness for decision making.
Using the PtDA can support collaborative decision-making in routine clinical practice without extending the consultation time.
本研究旨在开发一种针对马来西亚抑郁症患者的会诊决策辅助工具，并评估其在会诊期间支持治疗决策的有效性。
在文献综述和六个焦点小组之后开发了决策辅助工具原型。阿尔法测试通过以用户为中心的认知访谈评估其可理解性、可接受性、可用性和可取性。贝塔测试使用SDM量表和PDMS评估其疗效的初步证据。通过记录会诊时间来评估可行性。
阿尔法测试表明，该决策辅助工具以患者为导向，具有可理解性、全面性、简洁性和客观性，设计吸引人。贝塔测试表明，从患者[83.32(13.92)对85.76(13.80)；p<0.05]和医生[81.07(10.09)对86.36(10.10)；p<0.05]的角度来看，患者决策辅助工具显著提高了患者对共同决策的满意度，并且从患者[PDMS患者：84.10(12.69)]和医生[PDMS医生：83.78(16.62)]的角度来看，也让患者为决策做好了准备。对照组和干预组之间的会诊时间没有变化。
我们为马来西亚抑郁症患者开发了一种抗抑郁患者决策辅助工具，该工具增加了患者在共同决策中的参与度，并提高了他们的决策准备程度。
使用患者决策辅助工具可以在不延长会诊时间的情况下支持常规临床实践中的协作决策。
